Nanjing

Researchers are evaluating the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for treating pre- and postmenopausal women and men with locally advanced or metastatic estrogen receptor positive ERhuman epidermal growth factor 2 negative HER2- breast cancer who have an ESR1 mutation and have previously been treated with ribociclib or palbociclib. The study aims to compare the effectiveness, safety, and tolerability of these two treatment combinations. Participants are randomly assigned to one of two groups one receives 5 mg daily oral lasofoxifene plus oral abemaciclib 150 mg twice a day the other receives fulvestrant 500 mg via intramuscular injections on Days 1, 15, and 29 and then monthly thereafter, combined with oral abemaciclib 150 mg twice a day. This open-label study assesses these treatments over approximately three years. During the trial, participants will be monitored through regular assessments including tumor measurements, survival tracking, quality of life questionnaires, and evaluation of adverse events. Researchers will measure progression-free survival as the primary outcome and also track response rates, overall survival, treatment duration, and time to chemotherapy. Brain metastases patients meeting specific criteria are allowed, and safety is closely observed throughout the study period which may last up to about three years.

Researchers are studying patients with coronary artery disease undergoing primary isolated non-emergency coronary artery bypass surgery CABG. The trial compares the use of a single arterial graft versus multiple arterial grafts to assess whether multiple grafts reduce the combined risk of death, stroke, heart attack after discharge, and repeat revascularization, as well as improve overall survival. This international randomized trial involves over 4,300 patients across at least 25 centers and aims to provide clear evidence on the benefits of arterial graft strategies in heart surgery. Participants will be randomly assigned to one of two groups. The first group receives a single arterial graft using the left internal thoracic artery, supplemented by venous grafts as needed. The second group receives multiple arterial grafts, including the left internal thoracic artery plus either the right internal thoracic artery or the radial artery, with the possibility of additional arterial grafts. Treatment is delivered during CABG surgery, and patients are followed over time to observe outcomes. During the study, participants will be monitored for major events such as death, stroke, heart attacks, and the need for additional procedures. Researchers will track these primary outcomes starting 72 hours after surgery and also evaluate secondary outcomes like 30-day mortality, postoperative complications, wound healing, stroke, cause-specific deaths, and hospital readmissions over a follow-up period that may average five years. The trial uses a randomized design to fairly compare the two grafting approaches and includes detailed safety and outcome assessments throughout the study period.